Molecular risk assessment for breast cancer development in patients with ductal hyperplasias

Indira Poola, Jessy Abraham, Josephine J. Marshalleck, Qingqi Yue, Vinatha B. Lokeshwar, George Bonney, Robert L. DeWitty

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: It has been reported that approximately a million women are diagnosed with benign breast lesions that include ductal hyperplasias per year in the United States. Recent studies that followed women with benign lesions have established that about 8% to 9% of them will subsequently develop invasive breast cancer (IBC). However, currently, there are no means of identifying a subclass of "true precancerous tissues" in women with ductal hyperplasias who will subsequently develop cancer. The purpose of this study is to investigate whether expression of hyaluronoglucosaminidase 1 (HYAL1), a known tumor promoter, in hyperplastic tissues identifies a "true precancerous stage" and predicts subsequent IBC development. Experimental Design: A retrospective study was conducted with archival benign tissues of various histologic types and clinical information on development/nondevelopment of IBC. The control group was hyperplastic tissues from women who had no prior history of IBC and did not develop cancer in 5 to 7 years after diagnosis (n = 81). The test group was hyperplastic tissues from patients who developed cancer (n = 82). HYAL1 expression was studied by immunohistochemistry, and the results were statistically analyzed for significant association to develop cancer (P value), specificity, sensitivity, positive predictive value, and negative predictive value. Results: Statistical analysis of HYAL1 expression data showed very highly significant association between its expression and subsequent cancer development (P = 0) and very high sensitivity (0.83), specificity (0.84), positive predictive value (0.84), and negative predictive value (0.83). Conclusions: The expression of HYAL1 in ductal hyperplastic tissues is a strong predictor of subsequent development of IBC; therefore, it can be applied as a diagnostic marker either singly or in combination with other marker(s) to screen benign tissues to predict subsequent development of IBC. Detection at the precancerous stage and treatment could drastically cut down breast cancer incidence and deaths from it.

Original languageEnglish
Pages (from-to)1274-1280
Number of pages7
JournalClinical Cancer Research
Volume14
Issue number4
DOIs
StatePublished - Feb 15 2008
Externally publishedYes

Fingerprint

Hyperplasia
Breast Neoplasms
Hyaluronoglucosaminidase
Neoplasms
Sensitivity and Specificity
Carcinogens
Breast
Research Design
Retrospective Studies
Immunohistochemistry
Control Groups
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Poola, I., Abraham, J., Marshalleck, J. J., Yue, Q., Lokeshwar, V. B., Bonney, G., & DeWitty, R. L. (2008). Molecular risk assessment for breast cancer development in patients with ductal hyperplasias. Clinical Cancer Research, 14(4), 1274-1280. https://doi.org/10.1158/1078-0432.CCR-07-4053

Molecular risk assessment for breast cancer development in patients with ductal hyperplasias. / Poola, Indira; Abraham, Jessy; Marshalleck, Josephine J.; Yue, Qingqi; Lokeshwar, Vinatha B.; Bonney, George; DeWitty, Robert L.

In: Clinical Cancer Research, Vol. 14, No. 4, 15.02.2008, p. 1274-1280.

Research output: Contribution to journalArticle

Poola, I, Abraham, J, Marshalleck, JJ, Yue, Q, Lokeshwar, VB, Bonney, G & DeWitty, RL 2008, 'Molecular risk assessment for breast cancer development in patients with ductal hyperplasias', Clinical Cancer Research, vol. 14, no. 4, pp. 1274-1280. https://doi.org/10.1158/1078-0432.CCR-07-4053
Poola, Indira ; Abraham, Jessy ; Marshalleck, Josephine J. ; Yue, Qingqi ; Lokeshwar, Vinatha B. ; Bonney, George ; DeWitty, Robert L. / Molecular risk assessment for breast cancer development in patients with ductal hyperplasias. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 4. pp. 1274-1280.
@article{54a2a23d19424157b56f62a982278cf1,
title = "Molecular risk assessment for breast cancer development in patients with ductal hyperplasias",
abstract = "Purpose: It has been reported that approximately a million women are diagnosed with benign breast lesions that include ductal hyperplasias per year in the United States. Recent studies that followed women with benign lesions have established that about 8{\%} to 9{\%} of them will subsequently develop invasive breast cancer (IBC). However, currently, there are no means of identifying a subclass of {"}true precancerous tissues{"} in women with ductal hyperplasias who will subsequently develop cancer. The purpose of this study is to investigate whether expression of hyaluronoglucosaminidase 1 (HYAL1), a known tumor promoter, in hyperplastic tissues identifies a {"}true precancerous stage{"} and predicts subsequent IBC development. Experimental Design: A retrospective study was conducted with archival benign tissues of various histologic types and clinical information on development/nondevelopment of IBC. The control group was hyperplastic tissues from women who had no prior history of IBC and did not develop cancer in 5 to 7 years after diagnosis (n = 81). The test group was hyperplastic tissues from patients who developed cancer (n = 82). HYAL1 expression was studied by immunohistochemistry, and the results were statistically analyzed for significant association to develop cancer (P value), specificity, sensitivity, positive predictive value, and negative predictive value. Results: Statistical analysis of HYAL1 expression data showed very highly significant association between its expression and subsequent cancer development (P = 0) and very high sensitivity (0.83), specificity (0.84), positive predictive value (0.84), and negative predictive value (0.83). Conclusions: The expression of HYAL1 in ductal hyperplastic tissues is a strong predictor of subsequent development of IBC; therefore, it can be applied as a diagnostic marker either singly or in combination with other marker(s) to screen benign tissues to predict subsequent development of IBC. Detection at the precancerous stage and treatment could drastically cut down breast cancer incidence and deaths from it.",
author = "Indira Poola and Jessy Abraham and Marshalleck, {Josephine J.} and Qingqi Yue and Lokeshwar, {Vinatha B.} and George Bonney and DeWitty, {Robert L.}",
year = "2008",
month = "2",
day = "15",
doi = "10.1158/1078-0432.CCR-07-4053",
language = "English",
volume = "14",
pages = "1274--1280",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Molecular risk assessment for breast cancer development in patients with ductal hyperplasias

AU - Poola, Indira

AU - Abraham, Jessy

AU - Marshalleck, Josephine J.

AU - Yue, Qingqi

AU - Lokeshwar, Vinatha B.

AU - Bonney, George

AU - DeWitty, Robert L.

PY - 2008/2/15

Y1 - 2008/2/15

N2 - Purpose: It has been reported that approximately a million women are diagnosed with benign breast lesions that include ductal hyperplasias per year in the United States. Recent studies that followed women with benign lesions have established that about 8% to 9% of them will subsequently develop invasive breast cancer (IBC). However, currently, there are no means of identifying a subclass of "true precancerous tissues" in women with ductal hyperplasias who will subsequently develop cancer. The purpose of this study is to investigate whether expression of hyaluronoglucosaminidase 1 (HYAL1), a known tumor promoter, in hyperplastic tissues identifies a "true precancerous stage" and predicts subsequent IBC development. Experimental Design: A retrospective study was conducted with archival benign tissues of various histologic types and clinical information on development/nondevelopment of IBC. The control group was hyperplastic tissues from women who had no prior history of IBC and did not develop cancer in 5 to 7 years after diagnosis (n = 81). The test group was hyperplastic tissues from patients who developed cancer (n = 82). HYAL1 expression was studied by immunohistochemistry, and the results were statistically analyzed for significant association to develop cancer (P value), specificity, sensitivity, positive predictive value, and negative predictive value. Results: Statistical analysis of HYAL1 expression data showed very highly significant association between its expression and subsequent cancer development (P = 0) and very high sensitivity (0.83), specificity (0.84), positive predictive value (0.84), and negative predictive value (0.83). Conclusions: The expression of HYAL1 in ductal hyperplastic tissues is a strong predictor of subsequent development of IBC; therefore, it can be applied as a diagnostic marker either singly or in combination with other marker(s) to screen benign tissues to predict subsequent development of IBC. Detection at the precancerous stage and treatment could drastically cut down breast cancer incidence and deaths from it.

AB - Purpose: It has been reported that approximately a million women are diagnosed with benign breast lesions that include ductal hyperplasias per year in the United States. Recent studies that followed women with benign lesions have established that about 8% to 9% of them will subsequently develop invasive breast cancer (IBC). However, currently, there are no means of identifying a subclass of "true precancerous tissues" in women with ductal hyperplasias who will subsequently develop cancer. The purpose of this study is to investigate whether expression of hyaluronoglucosaminidase 1 (HYAL1), a known tumor promoter, in hyperplastic tissues identifies a "true precancerous stage" and predicts subsequent IBC development. Experimental Design: A retrospective study was conducted with archival benign tissues of various histologic types and clinical information on development/nondevelopment of IBC. The control group was hyperplastic tissues from women who had no prior history of IBC and did not develop cancer in 5 to 7 years after diagnosis (n = 81). The test group was hyperplastic tissues from patients who developed cancer (n = 82). HYAL1 expression was studied by immunohistochemistry, and the results were statistically analyzed for significant association to develop cancer (P value), specificity, sensitivity, positive predictive value, and negative predictive value. Results: Statistical analysis of HYAL1 expression data showed very highly significant association between its expression and subsequent cancer development (P = 0) and very high sensitivity (0.83), specificity (0.84), positive predictive value (0.84), and negative predictive value (0.83). Conclusions: The expression of HYAL1 in ductal hyperplastic tissues is a strong predictor of subsequent development of IBC; therefore, it can be applied as a diagnostic marker either singly or in combination with other marker(s) to screen benign tissues to predict subsequent development of IBC. Detection at the precancerous stage and treatment could drastically cut down breast cancer incidence and deaths from it.

UR - http://www.scopus.com/inward/record.url?scp=39749184110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749184110&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-4053

DO - 10.1158/1078-0432.CCR-07-4053

M3 - Article

VL - 14

SP - 1274

EP - 1280

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -